177A.T Stock - Kohjin Bio Co., Ltd.
Unlock GoAI Insights for 177A.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $5.21B | $4.77B | $4.74B | $3.95B |
| Gross Profit | $2.37B | $1.88B | $2.45B | $2.04B |
| Gross Margin | 45.4% | 39.4% | 51.7% | 51.7% |
| Operating Income | $991.13M | $596.82M | $1.27B | $969.58M |
| Net Income | $794.76M | $384.00M | $829.79M | $587.67M |
| Net Margin | 15.3% | 8.1% | 17.5% | 14.9% |
| EPS | $155.52 | $92.20 | $199.23 | $117.18 |
Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags and other materials; cryopreservation agent of cells; medium supplements; normal human cells; normal human cell mediums; ES cell mediums; in-vitro fertilization and early embryo culture kits; and other culture and related products, such as supplements, cell separation solutions, physiological salt solutions, and research reagents. The company also offers clinical microbiology culture mediums for gram positive cocci, gram negative bacteria, and susceptibility testing; general differential, anaerobic growth, and fungal mediums; tube mediums for confirmation and expansion; microbiology culture mediums for food, such as mediums for sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, and vibrio parahaemolyticus; culture mediums for determining total viable cell count; and campylobacter and fungal mediums. In addition, the company offers normal human blood, serum, and plasma; pathological human serum; preserved animal blood; defibrinated and hemolyzed animal blood; animal serum and plasma; and other custom-designed products, such as eagle medium. Further, the company engages in the production and sale of laboratory animal, sale of medical equipment, trust of animal immunization and antibody preparation, and import and export of products and raw materials. The company was formerly known as Kohjin Co.,Ltd and changed its name to Kohjin Bio Co., Ltd. in 1989. The company was incorporated in 1981 and is based in Sakado, Japan.
Visit WebsiteEarnings History & Surprises
177A.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $23.43 | — | — |
Q2 2025 | May 14, 2025 | — | $54.40 | — | — |
Q1 2025 | Feb 14, 2025 | — | $46.75 | — | — |
Q4 2024 | Nov 14, 2024 | — | $22.49 | — | — |
Q3 2024 | Aug 14, 2024 | — | $33.47 | — | — |
Q1 2024 | Mar 31, 2024 | — | $42.50 | — | — |
Q1 2024 | Mar 31, 2024 | — | $42.50 | — | — |
Latest News
Frequently Asked Questions about 177A.T
What is 177A.T's current stock price?
What is the analyst price target for 177A.T?
What sector is Kohjin Bio Co., Ltd. in?
What is 177A.T's market cap?
Does 177A.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 177A.T for comparison